Genrix Bio(688443.SH)

Company Encyclopedia
View More
name
Genrix Bio
688443.SH
Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family receptor bispecific antibody; GR2001, a monoclonal antibody; GR2201, a monoclonal antibody for VZV infection; GR1803, a bispecific antibody for multiple myeloma; GR1901, a bispecific antibody; WM202 a bispecific antibody; WM215, a single-domain antibody; GR1401, an anti-EGFR monoclonal antibody; and GR1405 an anti-PD-L1 monoclonal antibody. The company was founded in 2015 and is based in Chongqing, China.
1.700 T
688443.SHMarket value -Rank by Market Cap -/-

Financial Score

11/01/2026 Update
C
BiotechnologyIndustry
Industry Ranking35/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-28.18%E
    • Profit Margin-259.16%E
    • Gross Margin97.24%A
  • Growth ScoreB
    • Revenue YoY1560.46%A
    • Net Profit YoY25.13%B
    • Total Assets YoY-7.18%D
    • Net Assets YoY-24.03%E
  • Cash ScoreB
    • Cash Flow Margin-38.59%D
    • OCF YoY1560.46%A
  • Operating ScoreE
    • Turnover0.07E
  • Debt ScoreC
    • Gearing Ratio41.28%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    The A-share innovative drug sector surged in the afternoon, with WECOME rising over 15%, Frontier Biotechnologies and SHANGHAI YIZHONG rising over 10%, and JLPC, Hongbo Pharmaceutical, Genrix Bio, and Chengda Pharmaceutical following suit

    Wallstreetcn·
    SZ
    300878
    +20.01%
    SH
    688221
    +19.99%
    SH
    600513
    +10.01%
    Wallstreetcn·
    SZ
    300878
    +20.01%
    SH
    688221
    +19.99%
    SH
    600513
    +10.01%

    China Medical System Holdings Ltd. Announces Collaboration Agreements for Innovative Biologic Products

    China Medical System Holdings Ltd. has signed collaboration agreements for two innovative biologic products: Vecantoxatug Injection and Silevimig Injection. These agreements aim to enhance the company's business performance by leveraging synergies with its existing portfolio. The terms are deemed fair and reasonable by the company's directors, and the collaborating entity, Genrix Bio, is an independent third party. The transaction does not qualify as a connected or notifiable transaction under Hong Kong Stock Exchange Listing Rules.

    Reuters·
    SH
    688443
    +11.17%
    Reuters·
    SH
    688443
    +11.17%

    Genrix Bio signed a commercialization cooperation agreement for Weikang Duta monoclonal antibody injection and Sileweimi monoclonal antibody injection

    Genrix Bio has signed an exclusive cooperation agreement with CMS and RXILIENT for the exclusive rights to market Weikang Duta monoclonal injection and Sileweimi monoclonal injection. According to the agreement, Genrix Bio will receive an upfront payment and milestone payments, expected to total approximately RMB 510 million, while obtaining sales revenue in mainland China, the Asia-Pacific region, and North Africa. Tibet CMS and RXILIENT will respectively obtain exclusive commercialization rights for the aforementioned products in mainland China and other regions

    Zhitong·
    SH
    688443
    +11.17%
    HK
    00867
    +1.65%
    Zhitong·
    SH
    688443
    +11.17%
    HK
    00867
    +1.65%

    Genrix Bio's clinical trial application for the research product GR2301 injection has been approved

    Genrix Bio announced that its clinical trial application for the investigational product GR2301 injection has been approved by the National Medical Products Administration. GR2301 is a recombinant fully human anti-IL-15 monoclonal antibody designed to treat autoimmune diseases such as vitiligo caused by dysregulation of IL-15 expression

    Zhitong·
    SH
    688443
    +11.17%
    Zhitong·
    SH
    688443
    +11.17%

    Genrix Bio: The new drug application for Talikizumab injection has been accepted

    Genrix Bio announced that its Talizumab injection (GR1802) new drug application has been accepted by the National Medical Products Administration. This drug is used for the treatment of moderate to severe atopic dermatitis in adults and has achieved the primary endpoint in Phase III clinical trials. Talizumab is a recombinant fully human anti-IL-4Rα monoclonal antibody that can inhibit Th2-type inflammatory responses mediated by IL-4 or IL-13. The drug is also being developed for other indications

    Zhitong·
    SH
    688443
    +11.17%
    Zhitong·
    SH
    688443
    +11.17%
    © 2026 Longbridge｜Disclaimer